Clinical trial / 2006
In pure vegetarians, ezetimibe reduced cholesterol absorption by 58% and lowered LDL cholesterol by 17.3%.
A randomized, double-blind, placebo-controlled, two-phase crossover study in 18 healthy pure vegetarians evaluated the effect of ezetimibe (10 mg/day) over 2-week treatment periods separated by a 2-week washout. Mean dietary cholesterol intake was 29.4 +/- 16.8 mg/day during the placebo phase and 31.4 +/- 14.4 mg/day during the ezetimibe phase. Fractional cholesterol absorption decreased by 58% from 48.2 +/- 8.2% on placebo to 20.2 +/- 6.2% on ezetimibe (P < 0.001), accompanied by a significant 17.3% reduction in LDL cholesterol.
- Study type
- Randomized, double-blind, placebo-controlled crossover study
- Who was studied
- 18 healthy pure vegetarians
- What was measured
- Plasma lipids, fractional cholesterol absorption, and cholesterol synthesis
THE PAPER
The lipid-lowering effect of ezetimibe in pure vegetarians.
Clarenbach JJ, Reber M, Lütjohann D, von Bergmann K, Sudhop T. J Lipid Res, 2006.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.